Decades of tracking reveals: This commonly used "fetal protection drug" may double the risk of cancer in future generations

Supplementing natural progesterone or synthetic progesterone is a common treatment strategy to prevent spontaneous preterm birth

However, a new study recently published in the academic journal American Journal of Obstetrics and Gynecology pointed out that exposure to the offspring of 17-OHPC in the uterus may increase the risk of cancer

In order to investigate the long-term effects of 17-OHPC on the health of offspring, the researchers analyzed the prenatal care records of tens of thousands of mothers and babies in California from 1959 to 1966, and tracked the children born through the California Cancer Registry.

Among 18,751 children born, 1,008 were diagnosed with cancer between the ages of 0 and 58

Researchers analyzed the data and found that fetuses exposed to 17-OHPC in the first trimester of pregnancy are more likely to detect cancer in the future, including colorectal cancer, prostate cancer, and childhood brain tumors

Research institutions mentioned that the US FDA proposed to withdraw the drug from the market in October 2020

Note: The original text has been deleted

Reference materials:

[1] Caitlin C.

[2] Drug used to prevent miscarriage increases risk of cancer in offspring.